Is an every‑other‑day (EOD) aspirin regimen appropriate for antiphospholipid syndrome?

Every-Other-Day Aspirin is NOT Appropriate for Antiphospholipid Syndrome

Every-other-day (EOD) aspirin dosing is inappropriate for APS management—when aspirin is indicated, it must be given as a daily low-dose regimen (75-100 mg once daily). There is no evidence supporting alternate-day dosing for this condition, and such an approach would provide inadequate antiplatelet coverage for thrombosis prevention.

When Daily Low-Dose Aspirin IS Indicated in APS

Based on the most recent EULAR guidelines, daily low-dose aspirin (LDA) is recommended specifically for 1:

• Asymptomatic aPL carriers with high-risk antibody profiles (triple positive or persistently high titers)
• Patients with systemic lupus erythematosus who have positive aPL but no prior thrombotic or obstetric APS
• Non-pregnant women with history of obstetric APS only (no thrombotic events), particularly with high-risk profiles
• Combination therapy with anticoagulation in arterial thrombosis cases (may be considered)
• Pregnant women with prior obstetric APS (combined with prophylactic heparin) 1

The Dosing Must Be Daily

The evidence base for aspirin in APS consistently uses daily dosing at 75-100 mg 2, 1. The European Society of Cardiology guidelines explicitly state that "aspirin once daily is recommended in all clinical conditions in which antiplatelet prophylaxis has a favourable benefit/risk profile" and that "daily doses of aspirin in the range of 75-100 mg" are supported for long-term prevention 2.

Key point: The APLASA trial, which evaluated aspirin for primary prevention in asymptomatic aPL-positive individuals, used 81 mg daily (not EOD) and found no benefit in low-risk patients without additional thrombosis risk factors 3. This underscores that even daily dosing may not benefit all aPL-positive patients, making EOD dosing even less justifiable.

Clinical Algorithm for Aspirin Use in APS

For asymptomatic aPL-positive patients:

• Check antibody profile (triple positive = high risk)
• Assess for additional cardiovascular risk factors
• If high-risk profile OR additional risk factors present → Daily LDA 75-100 mg 1, 4
• If low-risk profile and no additional risk factors → Consider observation (aspirin benefit uncertain) 3

For patients with prior thrombotic APS:

• Venous thrombosis → Vitamin K antagonist (INR 2-3) is primary treatment; aspirin generally not added 1
• Arterial thrombosis → VKA (INR 2-3 or 3-4) ± daily LDA 1, 4
• Recurrent thrombosis despite adequate anticoagulation → Consider adding daily LDA 1

For obstetric APS:

• During pregnancy → Daily LDA + prophylactic heparin 1, 5
• Outside pregnancy (no thrombotic history) → Daily LDA if high-risk profile 1

Critical Pitfalls to Avoid

1. Never use EOD dosing—this provides inadequate platelet inhibition and has no evidence base in APS
2. Don't use aspirin alone for thrombotic APS—anticoagulation with VKA is the cornerstone; aspirin is adjunctive at best 6, 1
3. Don't assume all aPL-positive patients need aspirin—the APLASA trial showed low-risk asymptomatic carriers had minimal thrombosis rates without treatment 3
4. Risk stratification is essential—triple positivity (LA + anticardiolipin + anti-β2GPI) identifies high-risk patients who benefit most from prophylaxis 1, 4

Why EOD Dosing Fails

Aspirin irreversibly inhibits platelet cyclooxygenase, but new platelets are continuously produced (approximately 10% daily turnover). Daily dosing ensures consistent inhibition of the entire platelet pool, which is critical for preventing thrombosis in a prothrombotic condition like APS. EOD dosing would leave gaps in antiplatelet coverage, particularly problematic given that APS involves both platelet activation and endothelial dysfunction 6.

The standard dose is 75-100 mg daily 2, 1, with 81 mg being the most commonly used dose in clinical trials 3. Some protocols use a 160 mg loading dose in acute situations, followed by daily maintenance 2.